Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | PGR | P06401 | 7/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509117 | 0.92 | KCNH2 (0.53) | KCNH2PGRPTGDR2 | |
| Cadaverine Tartrate SCHEMBL508832 | 0.91 | KCNH2 (0.45) | KCNH2PGRPTGDR2MGLL | |
| Phosphoric Acid SCHEMBL509020 | 0.90 | KCNH2 (0.47) | KCNH2PGRPTGDR2MGLL | |
| Citric Acid SCHEMBL508959 | 0.89 | KCNH2 (0.42) | KCNH2PGRPTGDR2MGLL | |
| SCHEMBL509346 | 0.86 | KCNH2 (0.51) | KCNH2PGR | |
| SCHEMBL2716851 | 0.86 | KCNH2 (0.49) | KCNH2PGR | |
| SCHEMBL2717137 | 0.84 | KCNH2 (0.53) | KCNH2PGRPTGDR2MGLL | |
| SCHEMBL509725 | 0.83 | KCNH2 (0.44) | KCNH2PGR | |
| SCHEMBL2718123 | 0.81 | KCNH2 (0.54) | KCNH2PGRPTGDR2 | |
| SCHEMBL4818364 | 0.81 | KCNH2 (0.42) | KCNH2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | claimed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | claimed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | claimed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | claimed |
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | KCNH2 3441/4885PGR 641/4885PTGDR2 3222/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | KCNH2 3304/4885PGR 893/4885PTGDR2 3365/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | KCNH2 3548/4885PGR 891/4885PTGDR2 3632/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | KCNH2 3503/4885PGR 1045/4885PTGDR2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.